Perrigo (0Y5E) Stock Overview
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
0Y5E Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Perrigo Company plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.46 |
| 52 Week High | US$30.81 |
| 52 Week Low | US$23.21 |
| Beta | 0.45 |
| 1 Month Change | -0.92% |
| 3 Month Change | -4.69% |
| 1 Year Change | 1.09% |
| 3 Year Change | -34.43% |
| 5 Year Change | -51.52% |
| Change since IPO | -71.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Y5E | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 1.3% | -2.3% | 0.08% |
| 1Y | 1.1% | -12.2% | 5.1% |
Return vs Industry: 0Y5E exceeded the UK Pharmaceuticals industry which returned -11.6% over the past year.
Return vs Market: 0Y5E underperformed the UK Market which returned 5.6% over the past year.
Price Volatility
| 0Y5E volatility | |
|---|---|
| 0Y5E Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.8% |
| 10% least volatile stocks in GB Market | 3.3% |
Stable Share Price: 0Y5E has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0Y5E's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 8,379 | Patrick Lockwood-Taylor | www.perrigo.com |
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Perrigo Company plc Fundamentals Summary
| 0Y5E fundamental statistics | |
|---|---|
| Market cap | US$3.65b |
| Earnings (TTM) | -US$164.70m |
| Revenue (TTM) | US$4.34b |
Is 0Y5E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Y5E income statement (TTM) | |
|---|---|
| Revenue | US$4.34b |
| Cost of Revenue | US$2.76b |
| Gross Profit | US$1.58b |
| Other Expenses | US$1.74b |
| Earnings | -US$164.70m |
Last Reported Earnings
Mar 29, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 36.38% |
| Net Profit Margin | -3.80% |
| Debt/Equity Ratio | 83.5% |
How did 0Y5E perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/30 08:41 |
| End of Day Share Price | 2025/06/30 00:00 |
| Earnings | 2025/03/29 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Perrigo Company plc is covered by 37 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Douglas Tsao | Barclays |